Researchers examined whether CDK4/6 inhibitors lead to better overall survival when used as first- or second-line treatment.
US FDA accepts Roche’s NDA for giredestrant in ESR1-mutated, ER-positive advanced breast cancer: Basel Saturday, February 21, 2026, 11:00 Hrs [IST] Roche announced that the Unit ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application for giredestrant, ...
The NDA is based on results from the Phase III evERA Breast Cancer study. Credit: NMK-Studio / Shutterstock.com. (NMK-Studio / Shutterstock.com.) Roche has obtained acceptance from the US Food and ...
Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or ...
Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus ...
The FDA application is supported by data from the Phase 3 evERA Breast Cancer study. The trial results showed that the combination of giredestrant and Afinitor reduced the risk of disease progression ...
New study reveals how cytoplasmic and nuclear functions of USP30-AS1 converge to promote tumor growth Breast cancer progression is increasingly ...
Shanghai Simcere Pharmaceutical R&D Co. Ltd. has discovered CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.
Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that Itovebi® (inavolisib) is the first breast cancer therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results